EUCTR2018-002911-80-IT进行中（未招募）1 期
Open-label study to evaluate the safety, tolerability, and efficacy of LOmitapide for the treatment of patients with Familial CHylomicroNEmia Syndrome - LOCHNES
PRM|212180 个研究点目标入组 20 人开始时间: 2020年5月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Written informed consent
- •2.Age = 18 years at time of informed consent
- •3.History of chylomicronemia as evidenced by documentation of lactescent serum or documentation of fasting TG measurement = 885 mg/dl (10 mmol/L)
- •4.A diagnosis of Familial Chylomicronemia Syndrome by documentation of at least one of the following: confirmed homozygote, compound heterozygote or double heterozygote for known loss-of-function mutations in genes causing FCS
- •5.Fasting TG = 750 mg/dl (8.4 mmol/L) at screening
- •6.History of pancreatitis
- •7.Willing to follow a diet comprising = 20 g fat per day during the study con quanto riportato a pag. 21 Screening procedures include also dietary counseling with regard to low-fat diet (=20% energy from fat) and to avoid alcohol completely while receiving Lomitapide
- •8.Satisfy one of the following:
- •Females: non-pregnant and non-lactating; surgically sterile, post-menopausal, abstinent, or if engaged in sexual relations of child-bearing potential, patient is using an acceptable contraceptive method
- •Males: Surgically sterile, abstinent or if engaged in sexual relations with a female of child-bearing potential, patient is utilizing an acceptable contraceptive method
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 17
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 3
排除标准
- •1.Diabetes mellitus with any of the following: newly diagnosed within 12 weeks of screening; HbA1c = 9.0% at screening; recent change in anti-diabetic pharmacotherapy; anticipated need to change dose or type of medication during the treatment period of the study; current use of GLP-1 agonists.
- •2.Severe hypertriglyceridemia other than due to FCS.
- •3.Active pancreatitis within 4 weeks prior to screening.
- •4.History within 6 months of screening of acute or unstable cardiac ischemia, stroke, transient ischemic attack or unstable congestive cardiac failure requiring a change in medication or major surgery within 3 months of screening.
- •5.Any of the following laboratory values at screening: total bilirubin > upper limit of normal (ULN); AST > 2.0 x ULN; ALT > 2.0 x ULN; persistently positive for protein on urine dipstick; persistently positive for blood or urine dipstick; estimated creatinine clearance calculated according to the formula of Cockcroft and Gault < 50 mL/min.
- •6.Uncontrolled hypertension (BP > 160/100 mmHg).
- •7.History of bleeding diathesis or coagulopathy or clinically significant abnormality in coagulation parameters at screening.
- •8.History of heart failure with NYHA greater than Class II.
- •9.Active infection requiring systemic antiviral or antimicrobial therapy that will not be completed prior to begin treatment with Lomitapide (Baseline Visit).
- •10.Known history of or positive test for human immunodeficiency virus (HIV), hepatitis C or chronic hepatitis B.
- •11.Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated.
- •12.Treatment with another investigational drug, biological agent, or device within one month of screening, or 5 half-lives of investigational agent, whichever is longer.
- •13.Unwilling to comply with lifestyle requirements.
- •14. Known lactose intolerance.
- •15. Use of the following:
- •Statins, omega-3 fatty acids or fibrates unless on a stable dose for at least 3 months prior to screening and dose and regimen expected to remain constant during the treatment period. Patients taking omega-3 fatty acids should make every effort to remain on the same brand throughout the study
- •Nicotinic acid or derivatives of nicotinic acid within 4 weeks prior to screening
- •Systemic corticosteroids or anabolic steroids within 6 weeks prior to screening unless approved by the Investigator
- •Atypical antipsychotic medications unless on a stable dose for at least 4 weeks prior to screening and dose and regimen expected to remain constant during the treatment period
- •Glybera gene therapy within 2 years prior to screening
- •Oral anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, and apixaban) unless on a stable dose for at least 4 weeks prior to screening and regular clinical monitoring is performed
- •Tamoxifen, estrogens or progestins unless on a stable dose for at least 4 months prior to screening and dose and regimen expected to remain constant during the treatment period
- •Plasma apheresis within 4 weeks prior to screening or planned during the study
- •Any of the medication unless stable at least 4 weeks prior to screening
- •16.Blood donation of 50 to 499 mL within 30 days of screening or of > 499 mL within 60 days of screening
- •17.Have any other conditions, which, in the opinion of the Investigators or the Sponsor would make the patient unsuitable for inclusion, or could interfere with the patient participating in or completi
研究者
相似试验
招募中
1 期
Phase I study of a Latanoprost Ocular Implant for treatment of Open Angle Glaucoma or Ocular Hypertension.Ocular HypertensionACTRN12621001718831PolyActiva Pty Ltd6
已完成
3 期
An open-label study to assess the safety, tolerability and multiple-dose phamacokinetics of AA4500 0.58 mg in subjects with Dupuytren's contractures.ACTRN12610001045000Auxilium Phamaceuticals, Inc.12
进行中（未招募）
不适用
A study to look at the effect of the study drug on heart muscle thickness, the amount of drug that ends up in the blood, and the safety and tolerability of study drug in Noonan syndrome patients.oonan syndrome hypertrophic cardiomyopathyMedDRA version: 14.1Level: PTClassification code 10029748Term: Noonan syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 14.1Level: PTClassification code 10020871Term: Hypertrophic cardiomyopathySystem Organ Class: 10007541 - Cardiac disordersEUCTR2011-003392-10-GBovartis Pharma Services AG22
进行中（未招募）
1 期
The VIOLIN Study: to Evaluate etravirine Tolerability, Pharmacokinetics With Other Antiretrovirals In Treatment Experienced PatientsEUCTR2010-023532-16-ROJanssen R&D Ireland211
已完成
1 期
A study to evaluate the safety, tolerability, and pharmacokinetics of a medicinal cannabinoid oil formulation in chronic non-cancer pain participants on long term opioid treatmentschronic painAnaesthesiology - Pain managementACTRN12619001013156Zelda Therapeutics9